GALILEO: rivaroxaban-based antithrombotic strategy vs. antiplatelet-based strategy after TAVR

GALILEO: rivaroxaban-based antithrombotic strategy vs. antiplatelet-based strategy after TAVR

Mirvat Al Asnag interviews Marco Valgimigli (GALILEO Trial Steering Committee) on the primary results of the GALILEO trial which were presented at the American Heart Association 2019 in Philadelphia. More news on #AHA19 late-breaking science here: https://www.pcronline.com/News/Whats-...